Antje Hoering

Also affiliated with Cancer Research And Biostatistics, Seattle University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial”.

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30354-9

N/A

3.8DataRank · unranked

126 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Hita +12 more

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Blood(2024)10.1182/blood.2024025939

N/A

0.621DataRank · unranked

10 citations

Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar +9 more

Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2119

N/A

0.456DataRank · unranked

8 citations

Rachael Sexton, Antje Hoering, Frits van Rhee, Bart Barlogie, Robert Z. Orlowski +1 more

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Blood Cancer Journal(2022)10.1038/s41408-022-00695-5

N/A

0DataRank · unranked

61 citations

Lawrence Baizer, Natalie S. Callander, Sergio Giralt, Jens Hillengaß, Boris Freidlin +11 more

Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.8054

N/A

0DataRank · unranked

4 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Jason Valent +11 more

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Blood Cancer Journal(2020)10.1038/s41408-020-0311-8

N/A

0DataRank · unranked

252 citations

Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar +8 more

Title Pending 371

Journal of the Society for Clinical Data Management(2024)10.47912/jscdm.371

N/A

0DataRank · unranked

1 citations

Chris Cook, Dani Weatherbee, Sunita Yadav, Dinesh Pal Mudaranthakam, Rachael Sexton +14 more

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns

Blood Cancer Journal(2020)10.1038/s41408-020-0336-z

N/A

0DataRank · unranked

38 citations

Eileen M. Boyle, Cody Ashby, Yan Wang, Valeriy V. Lyzogubov, Christopher P. Wardell +16 more

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8507

N/A

0DataRank · unranked

26 citations

Sikander Ailawadhi, Rachael Sexton, Antje Hoering, Brea Lipe, Sandi Hita +9 more